# HCW9218 for Advanced Pancreatic Cancer

> **NCT05304936** · PHASE1,PHASE2 · COMPLETED · sponsor: **ImmunityBio, Inc.** · enrollment: 21 (actual)

## Conditions studied

- Advanced Pancreatic Carcinoma

## Interventions

- **DRUG:** HCW9218
- **DRUG:** Gemcitabine (GEM)
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT05304936
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-17
- **Primary completion:** 2025-02-15
- **Final completion:** 2025-02-15
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05304936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05304936, "HCW9218 for Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05304936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*